Kim A. Papp, Janusz Jaworski, Bartlomiej Kwiek, Jakub Trefler, Anna Dudek, Jacek C. Szepietowski, Nataliya Reznichenko, Joanna Narbutt, Wojciech Baran, Joanna Kolinek, Stefan Daniluk, Katarzyna Bartnicka-Maslowska, Adam Reich, Yuriy Andrashko, Sunghyun Kim, Yunju Bae, Dabee Jeon, Jinsun Jung, Hyunseung Lee, Woori Ko, YeJin Kim, Diamant Thaçi
Equivalent efficacy—mean per cent improvement from baseline in Psoriasis Area and Severity Index (PASI) score at Week (W) 12 (primary endpoint)—was demonstrated between CT-P43, a candidate ustekinumab biosimilar, and reference ustekinumab. This study further evaluated the efficacy, pharmacokinetics, safety and immunogenicity of CT-P43 vs. reference ustekinumab, including after switching to CT-P43 from reference ustekinumab, in patients with moderate-to-severe plaque psoriasis. In this double-blind Phase III trial, patients were randomised (1:1) to treatment with subcutaneous CT-P43 or reference ustekinumab (45/90 mg [baseline body weight ≤ 100/> 100 kg]). At W16, patients receiving reference ustekinumab were re-randomised (1:1) to either continue this treatment or switch to CT-P43; CT-P43-treated patients continued CT-P43. Study medication was administered at W16 (after re-randomisation), W28 and W40. Secondary efficacy endpoints, pharmacokinetics, safety and immunogenicity were evaluated until W52. At W16, 502 patients were re-randomised (n = 253 continued receiving CT-P43; n = 125 continued receiving reference ustekinumab; n = 124 switched to CT-P43). Mean (standard deviation) PASI scores at W52 were similar across groups (continuing CT-P43: 1.44 [2.921]; continuing reference ustekinumab: 1.33 [3.070]; switched: 1.93 [2.966]). At W52, similar proportions of patients continuing CT-P43, continuing reference ustekinumab and switching achieved ≥ 75% improvement in PASI score (n = 226 [89.3%], 116 [92.8%] and 111 [89.5%]), static Physician’s Global Assessment score of 0/1 (n = 215 [85.0%], 110 [88.0%] and 96 [77.4%]) and Dermatology Life Quality Index score of 0/1 (n = 150 [59.3%], 67 [53.6%] and 78 [62.9%]). Serum ustekinumab concentrations were comparable across groups. Proportions of patients experiencing treatment-emergent adverse events (TEAEs) were similar across groups; study medication–related TEAEs occurred in 14 (5.5%), 8 (6.4%) and 12 (9.7%) patients continuing CT-P43, continuing reference ustekinumab and switching, respectively. Switching did not increase antidrug antibody positivity. Results support the comparability of CT-P43 to reference ustekinumab. Efficacy was maintained after switching to CT-P43 from reference ustekinumab, without notable safety or immunogenicity findings.
{"title":"Efficacy and Safety of CT-P43, a Candidate Ustekinumab Biosimilar, in Moderate-to-Severe Plaque Psoriasis: 52-Week Results From a Randomised, Active-Controlled, Double-Blind, Phase III Study","authors":"Kim A. Papp, Janusz Jaworski, Bartlomiej Kwiek, Jakub Trefler, Anna Dudek, Jacek C. Szepietowski, Nataliya Reznichenko, Joanna Narbutt, Wojciech Baran, Joanna Kolinek, Stefan Daniluk, Katarzyna Bartnicka-Maslowska, Adam Reich, Yuriy Andrashko, Sunghyun Kim, Yunju Bae, Dabee Jeon, Jinsun Jung, Hyunseung Lee, Woori Ko, YeJin Kim, Diamant Thaçi","doi":"10.1155/dth/8811546","DOIUrl":"https://doi.org/10.1155/dth/8811546","url":null,"abstract":"<p>Equivalent efficacy—mean per cent improvement from baseline in Psoriasis Area and Severity Index (PASI) score at Week (W) 12 (primary endpoint)—was demonstrated between CT-P43, a candidate ustekinumab biosimilar, and reference ustekinumab. This study further evaluated the efficacy, pharmacokinetics, safety and immunogenicity of CT-P43 vs. reference ustekinumab, including after switching to CT-P43 from reference ustekinumab, in patients with moderate-to-severe plaque psoriasis. In this double-blind Phase III trial, patients were randomised (1:1) to treatment with subcutaneous CT-P43 or reference ustekinumab (45/90 mg [baseline body weight ≤ 100/> 100 kg]). At W16, patients receiving reference ustekinumab were re-randomised (1:1) to either continue this treatment or switch to CT-P43; CT-P43-treated patients continued CT-P43. Study medication was administered at W16 (after re-randomisation), W28 and W40. Secondary efficacy endpoints, pharmacokinetics, safety and immunogenicity were evaluated until W52. At W16, 502 patients were re-randomised (<i>n</i> = 253 continued receiving CT-P43; <i>n</i> = 125 continued receiving reference ustekinumab; <i>n</i> = 124 switched to CT-P43). Mean (standard deviation) PASI scores at W52 were similar across groups (continuing CT-P43: 1.44 [2.921]; continuing reference ustekinumab: 1.33 [3.070]; switched: 1.93 [2.966]). At W52, similar proportions of patients continuing CT-P43, continuing reference ustekinumab and switching achieved ≥ 75% improvement in PASI score (<i>n</i> = 226 [89.3%], 116 [92.8%] and 111 [89.5%]), static Physician’s Global Assessment score of 0/1 (<i>n</i> = 215 [85.0%], 110 [88.0%] and 96 [77.4%]) and Dermatology Life Quality Index score of 0/1 (<i>n</i> = 150 [59.3%], 67 [53.6%] and 78 [62.9%]). Serum ustekinumab concentrations were comparable across groups. Proportions of patients experiencing treatment-emergent adverse events (TEAEs) were similar across groups; study medication–related TEAEs occurred in 14 (5.5%), 8 (6.4%) and 12 (9.7%) patients continuing CT-P43, continuing reference ustekinumab and switching, respectively. Switching did not increase antidrug antibody positivity. Results support the comparability of CT-P43 to reference ustekinumab. Efficacy was maintained after switching to CT-P43 from reference ustekinumab, without notable safety or immunogenicity findings.</p><p><b>Trial Registration:</b> ClinicalTrials.gov identifier: NCT04673786</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8811546","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147299963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Y. Hong and K. Y. Park, “Pilot Study on the Efficacy of a Dual-Length Microneedle Radiofrequency Device With Microblade Design for Neck Rejuvenation,” Dermatologic Therapy, https://doi.org/10.1155/dth/8855222.
In the Funding section of the article, the statement “No funding was received for this research.” was incorrect.
This should have read:
“This work was supported by the Technology Innovation Program (or Industrial Strategic Technology Development Program-Material and Component Technology Development Project [Heterogeneous Technology Convergence Type] [20024946, Development of Tissue Regenerative Biosurgery Convergence Medical Products Using High-Functional Implantable Biomaterials]) funded by the Ministry of Trade, Industry & Energy (MOTIE, Korea).”
We apologize for this error.
J. Y. Hong和K. Y. Park，“双长度微针射频装置与微刀设计用于颈部年轻化的有效性的试点研究”，《皮肤疗法》，https://doi.org/10.1155/dth/8855222.In文章的资助部分，“没有收到这项研究的资助”的声明是不正确的。这应该是：“这项工作得到了技术创新计划(或工业战略技术开发计划-材料和组件技术开发项目[异质技术融合型][20024946，使用高功能可植入生物材料的组织再生生物外科融合医疗产品的开发]的支持，由贸易，工业和能源部（MOTIE，韩国）资助。”我们为这个错误道歉。
{"title":"Correction to “Pilot Study on the Efficacy of a Dual-Length Microneedle Radiofrequency Device With Microblade Design for Neck Rejuvenation”","authors":"","doi":"10.1155/dth/9813767","DOIUrl":"https://doi.org/10.1155/dth/9813767","url":null,"abstract":"<p>J. Y. Hong and K. Y. Park, “Pilot Study on the Efficacy of a Dual-Length Microneedle Radiofrequency Device With Microblade Design for Neck Rejuvenation,” <i>Dermatologic Therapy</i>, https://doi.org/10.1155/dth/8855222.</p><p>In the Funding section of the article, the statement “No funding was received for this research.” was incorrect.</p><p>This should have read:</p><p>“This work was supported by the Technology Innovation Program (or Industrial Strategic Technology Development Program-Material and Component Technology Development Project [Heterogeneous Technology Convergence Type] [20024946, Development of Tissue Regenerative Biosurgery Convergence Medical Products Using High-Functional Implantable Biomaterials]) funded by the Ministry of Trade, Industry & Energy (MOTIE, Korea).”</p><p>We apologize for this error.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9813767","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147320938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Although various therapies are available for pressure ulcers, no single treatment has demonstrated superior effectiveness compared to others. Arnebia euchroma exhibits anti-inflammatory properties that facilitate the healing of surgical wounds and burns. We aimed to evaluate the efficacy of A. euchroma root ointment for the treatment of pressure ulcers.
Methods
This double-blind randomized controlled trial included 20 patients with Stage I–III pressure ulcers from nursing homes and medical facilities in Sari, Mazandaran, Iran, in 2020-2021. Patients were randomly assigned to two groups: Patients in the intervention group received Arnebia euchroma root 5% ointment, while those in the control group received silver sulfadiazine 1%. The primary outcome was improvement in the diameter and depth of the ulcer. Secondary outcomes were changed in the Pressure Ulcer Scale for Healing (PUSH) and side effects. Outcomes were assessed before intervention and then at one, two, three, and 4 weeks.
Results
Patients in both groups were comparable in terms of age, sex, nutritional disorders, use of antibedsore mattress, disease duration, underlying diseases, pressure ulcer stage, and pain, as well as baseline ulcer diameter, depth, and PUSH score. After 4 weeks, the ulcer depth was significantly lower in the intervention group than that in the control group (p < 0.001, standardized mean difference [SMD] = −2.43, 95% confidence interval [CI] −0.58; −1.23). Ulcer depth and diameter differences at other time points were not statistically significant. Mean PUSH scores did not differ significantly between groups at any time point. No side effects were observed in any of the patients.
Conclusions
A. euchroma root ointment can significantly reduce pressure ulcer depth after 4 weeks of application, with no significant effects on ulcer diameter and PUSH score. A. euchroma root ointment appears to be a safe treatment for pressure ulcers. These results need to be confirmed in larger randomized controlled trials.
Trial Registration: Iranian Registry of Clinical Trials (IRCT): IRCT20170818035762N4
{"title":"Arnebia euchroma Root Ointment for Pressure Ulcer Healing: A Double-Blind Randomized Controlled Trial","authors":"Armaghan Kazeminejad, Ebrahim Salehifar, Zahra Faghih, Mohammad Malekan, Amirreza Espahbodi, Mohtaram Andalib, Masoomeh Abdi Talarposhti, Nasim Gholizadeh","doi":"10.1155/dth/8929348","DOIUrl":"https://doi.org/10.1155/dth/8929348","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Although various therapies are available for pressure ulcers, no single treatment has demonstrated superior effectiveness compared to others. <i>Arnebia euchroma</i> exhibits anti-inflammatory properties that facilitate the healing of surgical wounds and burns. We aimed to evaluate the efficacy of <i>A. euchroma</i> root ointment for the treatment of pressure ulcers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This double-blind randomized controlled trial included 20 patients with Stage I–III pressure ulcers from nursing homes and medical facilities in Sari, Mazandaran, Iran, in 2020-2021. Patients were randomly assigned to two groups: Patients in the intervention group received <i>Arnebia euchroma</i> root 5% ointment, while those in the control group received silver sulfadiazine 1%. The primary outcome was improvement in the diameter and depth of the ulcer. Secondary outcomes were changed in the Pressure Ulcer Scale for Healing (PUSH) and side effects. Outcomes were assessed before intervention and then at one, two, three, and 4 weeks.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Patients in both groups were comparable in terms of age, sex, nutritional disorders, use of antibedsore mattress, disease duration, underlying diseases, pressure ulcer stage, and pain, as well as baseline ulcer diameter, depth, and PUSH score. After 4 weeks, the ulcer depth was significantly lower in the intervention group than that in the control group (<i>p</i> < 0.001, standardized mean difference [SMD] = −2.43, 95% confidence interval [CI] −0.58; −1.23). Ulcer depth and diameter differences at other time points were not statistically significant. Mean PUSH scores did not differ significantly between groups at any time point. No side effects were observed in any of the patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p><i>A. euchroma</i> root ointment can significantly reduce pressure ulcer depth after 4 weeks of application, with no significant effects on ulcer diameter and PUSH score. <i>A. euchroma</i> root ointment appears to be a safe treatment for pressure ulcers. These results need to be confirmed in larger randomized controlled trials.</p>\u0000 \u0000 <p><b>Trial Registration:</b> Iranian Registry of Clinical Trials (IRCT): IRCT20170818035762N4</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8929348","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147280939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Haiyan Weng, Pengfei Cha, Yan Wan, Ying Chen, Lili Xu, Yang Chen
Background
Androgenetic alopecia (AGA) is a chronic progressive disorder that may lead to permanent hair loss and associated psychosocial issues if left untreated. Although botulinum toxin (BTX) has been proposed as a potential therapeutic option for AGA, the evidence regarding its efficacy remains controversial.
Objectives
This study aims to evaluate the efficacy of BTX monotherapy for AGA through a systematic review and meta-analysis.
Methods
We conducted a comprehensive search of PubMed, Embase, and the Cochrane Library to identify randomized controlled trials (RCTs) utilizing BTX for AGA treatment. The primary outcome was hair density (hair count/cm2).
Results
A total of 7 studies involving 232 treatment units were included. The pooled within-group change showed a mean increase of 24.51 hairs/cm2 (95% CI: 10.22, 16.76) following BTX treatment. Subgroup analyses indicated that a significant increase in hair density was observed after 6 months of treatment, with an optimal injection dose of 100 U. Reinjection every 6 months was associated with significant hair density improvement. In addition, male participants demonstrated a more pronounced increase in hair density compared to mixed-gender cohorts (p = 0.0003). The therapeutic effect of BTX was more reliably estimated in studies with larger sample sizes.
Conclusion
BTX monotherapy yielded significant within-group improvements in hair density and diameter among AGA patients. Subgroup analyses indicated that 100 U dosing with 6-month intervals may optimize therapeutic outcomes. These findings warrant validation in large-scale, randomized, placebo-controlled trials to establish definitive clinical utility.
{"title":"The Efficacy of Botulinum Toxin in the Treatment of Androgenetic Alopecia: A Meta-Analysis","authors":"Haiyan Weng, Pengfei Cha, Yan Wan, Ying Chen, Lili Xu, Yang Chen","doi":"10.1155/dth/3919856","DOIUrl":"https://doi.org/10.1155/dth/3919856","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Androgenetic alopecia (AGA) is a chronic progressive disorder that may lead to permanent hair loss and associated psychosocial issues if left untreated. Although botulinum toxin (BTX) has been proposed as a potential therapeutic option for AGA, the evidence regarding its efficacy remains controversial.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This study aims to evaluate the efficacy of BTX monotherapy for AGA through a systematic review and meta-analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a comprehensive search of PubMed, Embase, and the Cochrane Library to identify randomized controlled trials (RCTs) utilizing BTX for AGA treatment. The primary outcome was hair density (hair count/cm<sup>2</sup>).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 7 studies involving 232 treatment units were included. The pooled within-group change showed a mean increase of 24.51 hairs/cm<sup>2</sup> (95% CI: 10.22, 16.76) following BTX treatment. Subgroup analyses indicated that a significant increase in hair density was observed after 6 months of treatment, with an optimal injection dose of 100 U. Reinjection every 6 months was associated with significant hair density improvement. In addition, male participants demonstrated a more pronounced increase in hair density compared to mixed-gender cohorts (<i>p</i> = 0.0003). The therapeutic effect of BTX was more reliably estimated in studies with larger sample sizes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>BTX monotherapy yielded significant within-group improvements in hair density and diameter among AGA patients. Subgroup analyses indicated that 100 U dosing with 6-month intervals may optimize therapeutic outcomes. These findings warrant validation in large-scale, randomized, placebo-controlled trials to establish definitive clinical utility.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/3919856","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146256430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Torres, A. Martorell, P. L. Felipe, et al., “Real-World Impact of Calcipotriol/Betamethasone Dipropionate Aerosol Foam on Quality of Life in Patients With Plaque Psoriasis: A Prospective Observational Study,” Dermatologic Therapy 2025, (2025): 7529636, https://doi.org/10.1155/dth/7529636
In the article, there was an error in the order of the last two authors. The author list has now been corrected in the article. The corrected author list is as follows:
Tiago Torres, Antonio Martorell, Paulo Leal Filipe, Caridad Soria, Fernando Mota, José Pardo, Ricardo Ruiz-Villaverde, Miquel Ribera
We apologize for this error.
T. Torres， A. Martorell， P. L. Felipe等，“钙三醇/二丙酸倍他米松气溶胶泡沫对斑块型银屑病患者生活质量的实际影响：一项前瞻性观察研究，”Dermatologic Therapy 2025, (2025): 7529636, https://doi.org/10.1155/dth/7529636In文章中，最后两位作者的顺序有误。文章中的作者名单现已更正。更正后的作者名单如下：Tiago Torres， Antonio Martorell, Paulo Leal Filipe, Caridad Soria, Fernando Mota, joses Pardo, Ricardo Ruiz-Villaverde, Miquel ribera。我们为这个错误道歉。
{"title":"Correction to “Real-World Impact of Calcipotriol/Betamethasone Dipropionate Aerosol Foam on Quality of Life in Patients With Plaque Psoriasis: A Prospective Observational Study”","authors":"","doi":"10.1155/dth/9795863","DOIUrl":"https://doi.org/10.1155/dth/9795863","url":null,"abstract":"<p>T. Torres, A. Martorell, P. L. Felipe, et al., “Real-World Impact of Calcipotriol/Betamethasone Dipropionate Aerosol Foam on Quality of Life in Patients With Plaque Psoriasis: A Prospective Observational Study,” <i>Dermatologic Therapy</i> 2025, (2025): 7529636, https://doi.org/10.1155/dth/7529636</p><p>In the article, there was an error in the order of the last two authors. The author list has now been corrected in the article. The corrected author list is as follows:</p><p>Tiago Torres, Antonio Martorell, Paulo Leal Filipe, Caridad Soria, Fernando Mota, José Pardo, Ricardo Ruiz-Villaverde, Miquel Ribera</p><p>We apologize for this error.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9795863","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147269036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Correction to “Effect of Oral Tranexamic Acid on Hair Melanin in Asian Women”","authors":"","doi":"10.1155/dth/9839203","DOIUrl":"https://doi.org/10.1155/dth/9839203","url":null,"abstract":"<p>Zhang, T., Li, J., Li, Y., Guo, Z., & Qi, X. (2025). Effect of Oral Tranexamic Acid on Hair Melanin in Asian Women. <i>Dermatologic Therapy</i>, 2025(1), 9071909. https://doi.org/10.1155/dth/9071909.</p><p>We apologize for these errors.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9839203","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147268907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Malignant atrophic papulosis (MAP) is the systemic subtype of Degos disease, characterized by high lethality. Currently there is no standardized treatment protocol. Steroids and immunosuppressive therapies result in limited effectiveness. Biologic treatments offer promising therapeutic potential for MAP and significantly improve prognosis.
Aims
This review aims to systematically evaluate the applications of various biologics in the treatment of MAP and to explore their potential efficacy.
Methods
We systematically searched three electronic databases (Scopus, Embase, and PubMed) from inception to November 30, 2025. All cases involving biologics for the treatment of MAP were included and analyzed.
Results
A total of six different biologics have been utilized in the treatment of MAP. Among all the biologics, eculizumab demonstrated the highest response rate, reaching 76.5% (n = 13/17). The use of rituximab has yielded inconsistent outcomes in the treatment of MAP. Neither tocilizumab nor natalizumab demonstrated satisfactory therapeutic efficacy, while the use of TNF inhibitors may result in disease exacerbation.
Conclusion
Eculizumab is recommended as a potential salvage therapy, and its combination with treprostinil may result in longer disease remission time. TNF inhibitors should be avoided in patients with MAP. More studies are needed to assess the long-term safety and efficacy of biologics in the treatment of MAP.
{"title":"New Advances in Biologic Treatment for Malignant Atrophic Papulosis: A Systematic Review","authors":"Jia-Wei Liu, Xiao Ma, Dong-Lai Ma","doi":"10.1155/dth/6276060","DOIUrl":"https://doi.org/10.1155/dth/6276060","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Malignant atrophic papulosis (MAP) is the systemic subtype of Degos disease, characterized by high lethality. Currently there is no standardized treatment protocol. Steroids and immunosuppressive therapies result in limited effectiveness. Biologic treatments offer promising therapeutic potential for MAP and significantly improve prognosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This review aims to systematically evaluate the applications of various biologics in the treatment of MAP and to explore their potential efficacy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We systematically searched three electronic databases (Scopus, Embase, and PubMed) from inception to November 30, 2025. All cases involving biologics for the treatment of MAP were included and analyzed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of six different biologics have been utilized in the treatment of MAP. Among all the biologics, eculizumab demonstrated the highest response rate, reaching 76.5% (<i>n</i> = 13/17). The use of rituximab has yielded inconsistent outcomes in the treatment of MAP. Neither tocilizumab nor natalizumab demonstrated satisfactory therapeutic efficacy, while the use of TNF inhibitors may result in disease exacerbation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Eculizumab is recommended as a potential salvage therapy, and its combination with treprostinil may result in longer disease remission time. TNF inhibitors should be avoided in patients with MAP. More studies are needed to assess the long-term safety and efficacy of biologics in the treatment of MAP.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6276060","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147275019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. M. Mueller, J. Zhu, O. Brandt, et al., “Serum Neurofilament Light Chain Levels Correlate With Skin Inflammation and Scratch Lesions in Patients With Pruritus,” Dermatologic Therapy, 2024, https://doi.org/10.1155/2024/3542876.
In the article, there is an error in the legend of Figure 1. The correct Figure legend is shown below:
Figure 1: Examples of patients’ SISL scores and their corresponding sNfL percentiles (based on healthy controls of same age and BMI) (a–c) and the correlation between sNfL percentiles and SISL scores (d). (a–c) Patients diagnosed with (a) atopic dermatitis, (b) suberythrodermic atopic dermatitis, and (c) erythrodermic atopic dermatitis. (d) Positive correlation between sNfL percentiles and the severity of skin inflammation and scratching injuries (as measured by the SISL score; Spearman’s rho = 0.70,p = 0.031, n = 10).
We apologize for this error.
S. M. Mueller， J. Zhu， O. Brandt等，“瘙痒患者血清神经丝轻链水平与皮肤炎症和抓痕病变相关”，《皮肤疗法》，2024年，https://doi.org/10.1155/2024/3542876.In文章，图1图例中有一个错误。图1：患者的SISL评分及其相应的sNfL百分位数（基于相同年龄和BMI的健康对照）（a - c）以及sNfL百分位数与SISL评分之间的相关性(d)。（a - c）诊断为(a)特应性皮炎、(b)亚红皮病特应性皮炎和(c)红皮病特应性皮炎的患者。(d) sNfL百分位数与皮肤炎症和抓伤严重程度呈正相关（以SISL评分衡量；Spearman’s rho = 0.70, p = 0.031, n = 10）。我们为这个错误道歉。
{"title":"Correction to “Serum Neurofilament Light Chain Levels Correlate With Skin Inflammation and Scratch Lesions in Patients With Pruritus”","authors":"","doi":"10.1155/dth/9762436","DOIUrl":"https://doi.org/10.1155/dth/9762436","url":null,"abstract":"<p>S. M. Mueller, J. Zhu, O. Brandt, et al., “Serum Neurofilament Light Chain Levels Correlate With Skin Inflammation and Scratch Lesions in Patients With Pruritus,” <i>Dermatologic Therapy</i>, 2024, https://doi.org/10.1155/2024/3542876.</p><p>In the article, there is an error in the legend of Figure 1. The correct Figure legend is shown below:</p><p><i>Figure 1: Examples of patients’ SISL scores and their corresponding sNfL percentiles (based on healthy controls of same age and BMI) (a–c) and the correlation between sNfL percentiles and SISL scores (d). (a–c) Patients diagnosed with (a) atopic dermatitis, (b) suberythrodermic atopic dermatitis, and (c) erythrodermic atopic dermatitis. (d) Positive correlation between sNfL percentiles and the severity of skin inflammation and scratching injuries (as measured by the SISL score; Spearman’s rho = 0.70,</i> <i>p</i> = 0.031<i>, n = 10)</i>.</p><p>We apologize for this error.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9762436","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146256439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Acitretin is used for psoriasis and for prevention of keratinocyte carcinomas. Almost all patients experience mucocutaneous side effects, such as dry mouth and xerosis. As these side effects are amplified in low-humidity environments, we sought to determine if humidity influenced the geographical prescription patterns of acitretin. Cross-sectional analysis was conducted at the state level from 2013 to 2019 using Medicare Part D Claims Data and the UN’s Food and Agriculture Organization’s (FAO) Climate Information Tool AgERA5 dataset. Using all states, relative humidity percentage was a statistically significant positive predictor of acitretin prescriptions per prescriber (β = 0.034, p = 0.038). The top 5 most humid states had higher acitretin prescriptions per prescriber (6.72 vs. 5.50, p = 0.015) compared to the bottom 5 least humid states. Moreover, the groups did not statistically significantly differ on acitretin cost ($812.36 vs. $807.29, p = 0.88), apremilast prescriptions per prescriber (9.46 vs. 8.23, p = 0.23), or apremilast cost ($2789.86 vs. $2884.37, p = 0.21). Relative humidity correlates with Medicare providers’ acitretin-prescribing habits with prescriptions decreasing in low-humidity environments. Recognizing the potential impact of climate on prescribing retinoids may help guide treatment for dermatologic conditions.
{"title":"Cross-Sectional Analysis of the Impact of Humidity on Acitretin Prescription Patterns Among Medicare Providers From 2013 to 2019","authors":"Yash Kumar, Bryan T. Carroll, Jake X. Wang","doi":"10.1155/dth/6177518","DOIUrl":"https://doi.org/10.1155/dth/6177518","url":null,"abstract":"<p>Acitretin is used for psoriasis and for prevention of keratinocyte carcinomas. Almost all patients experience mucocutaneous side effects, such as dry mouth and xerosis. As these side effects are amplified in low-humidity environments, we sought to determine if humidity influenced the geographical prescription patterns of acitretin. Cross-sectional analysis was conducted at the state level from 2013 to 2019 using Medicare Part D Claims Data and the UN’s Food and Agriculture Organization’s (FAO) Climate Information Tool AgERA5 dataset. Using all states, relative humidity percentage was a statistically significant positive predictor of acitretin prescriptions per prescriber (<i>β</i> = 0.034, <i>p</i> = 0.038). The top 5 most humid states had higher acitretin prescriptions per prescriber (6.72 vs. 5.50, <i>p</i> = 0.015) compared to the bottom 5 least humid states. Moreover, the groups did not statistically significantly differ on acitretin cost ($812.36 vs. $807.29, <i>p</i> = 0.88), apremilast prescriptions per prescriber (9.46 vs. 8.23, <i>p</i> = 0.23), or apremilast cost ($2789.86 vs. $2884.37, <i>p</i> = 0.21). Relative humidity correlates with Medicare providers’ acitretin-prescribing habits with prescriptions decreasing in low-humidity environments. Recognizing the potential impact of climate on prescribing retinoids may help guide treatment for dermatologic conditions.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6177518","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147275040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pyogenic paronychia with granulation tissue usually requires surgical intervention and preoperative inflammation control. We developed a modified surgical procedure (the mini-Winograd procedure) and an innovative method for preoperative inflammation control for such cases.
Methods and Materials
Between June 2022 and June 2023, 100 consecutive patients who underwent the mini-Winograd procedure were retrospectively analyzed, including 43 patients with preoperative nail groove drainage and 57 patients with traditional preoperative treatment. Perioperative conditions were compared.
Results
Preoperative inflammation (42.1% vs. 7.0%, p < 0.001), postoperative edema (36.8% vs. 14.0%, p = 0.020), and postoperative pain (VAS: 3.2 ± 1.6 vs. 2.3 ± 1.2, p = 0.001) were significantly less in patients with preoperative nail groove drainage. Patients with drainage gained earlier recovery in walking ability (3.1 ± 1.0 vs. 2.7 ± 1.1, p = 0.035). The logistic regression results indicated that the preoperative inflammation status was an independent risk factor for SSI (OR = 11.67; p < 0.001) and postoperative severe pain (OR = 22.73; p = 0.003).
Conclusion
The mini-Winograd procedure with preoperative nail groove drainage is an effective treatment for pyogenic paronychia with granulation tissue, which improves preoperative inflammation management, reduces postoperative pain, and enhances recovery.
背景：伴有肉芽组织的化脓性甲沟炎通常需要手术干预和术前炎症控制。我们开发了一种改良的手术程序（迷你winograd程序）和一种创新的术前炎症控制方法。方法与材料回顾性分析2022年6月至2023年6月连续100例mini-Winograd手术患者，其中术前行甲沟引流43例，术前传统治疗57例。比较围手术期情况。结果术前行甲沟引流的患者术前炎症（42.1% vs. 7.0%, p < 0.001）、术后水肿（36.8% vs. 14.0%, p = 0.020）、术后疼痛（VAS: 3.2±1.6 vs. 2.3±1.2,p = 0.001）明显减轻。引流组患者行走能力恢复较早（3.1±1.0 vs. 2.7±1.1,p = 0.035）。logistic回归结果显示术前炎症状态是SSI （OR = 11.67; p < 0.001）和术后剧烈疼痛（OR = 22.73; p = 0.003）的独立危险因素。结论微创winograd手术加术前甲沟引流是治疗化脓性甲沟炎伴肉芽组织的有效方法，可改善术前炎症处理，减轻术后疼痛，促进恢复。
{"title":"Mini-Winograd Procedure and Preoperative Nail Groove Drainage for Pyogenic Paronychia With Granulation Tissue","authors":"Meng-yi Zhang, Yue Yin","doi":"10.1155/dth/7025119","DOIUrl":"https://doi.org/10.1155/dth/7025119","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Pyogenic paronychia with granulation tissue usually requires surgical intervention and preoperative inflammation control. We developed a modified surgical procedure (the mini-Winograd procedure) and an innovative method for preoperative inflammation control for such cases.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Materials</h3>\u0000 \u0000 <p>Between June 2022 and June 2023, 100 consecutive patients who underwent the mini-Winograd procedure were retrospectively analyzed, including 43 patients with preoperative nail groove drainage and 57 patients with traditional preoperative treatment. Perioperative conditions were compared.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Preoperative inflammation (42.1% vs. 7.0%, <i>p</i> < 0.001), postoperative edema (36.8% vs. 14.0%, <i>p</i> = 0.020), and postoperative pain (VAS: 3.2 ± 1.6 vs. 2.3 ± 1.2, <i>p</i> = 0.001) were significantly less in patients with preoperative nail groove drainage. Patients with drainage gained earlier recovery in walking ability (3.1 ± 1.0 vs. 2.7 ± 1.1, <i>p</i> = 0.035). The logistic regression results indicated that the preoperative inflammation status was an independent risk factor for SSI (OR = 11.67; <i>p</i> < 0.001) and postoperative severe pain (OR = 22.73; <i>p</i> = 0.003).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The mini-Winograd procedure with preoperative nail groove drainage is an effective treatment for pyogenic paronychia with granulation tissue, which improves preoperative inflammation management, reduces postoperative pain, and enhances recovery.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/7025119","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147268894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号